Glypican-3 (GPC3) has emerged as a promising immunotherapeutic target for hepatocellular carcinoma (HCC). However, its ...

GRAIL represents a middle ground-a third way-in that its Galleri test has performed relatively well in the commercial market.

A quick look at FDA’s 2025 transparency moves, what CRLs are (and aren’t), how FAERS works and its limits, who can report, and where the agency is applying AI.

A Multi-Party Team represented by Carnegie Mellon University researchers and private industry partners has secured an award of up to $26.7 million from the Advanced Research Projects Agency for Health ...

Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) ...

In the pharmaceutical and biopharmaceutical industry, patient safety is a steadfast non-negotiable. Whether it is in the ...

A smart DNA-targeting test detects tuberculosis from tongue swabs with 74% sensitivity, providing a painless option to normal ...

The discoveries and progress in medicine, biology, and chemistry in the last decades have revolutionized diagnostic and ...

September is Blood Cancer Awareness Month. SCRI Oncology Partners says 10% of cancer cases are diagnosed as blood cancers each year. It affects affect your blood, bone marrow or lymphatic system and ...

A massive NIH-backed study reveals that COVID-19’s toll on smell may be more widespread and lasting than most realize. Even ...

ClearNote Health receives United Kingdom Conformity Assessed markings for its Avantect Multi-Cancer Detection Test and ...